Repurposing Licensed Drugs with Activity Against Epstein–Barr Virus for Treatment of Multiple Sclerosis: A Systematic ApproachVivien Li, Fiona C. McKay, David C. Tscharke et al.|CNS Drugs|2025Cited by 14
Coeliac disease as a model for understanding multiple sclerosisNatalia Drosu, Ludvig M. Sollid, Michael Levy et al.|Nature Reviews Neurology|2024Cited by 4